Savara ($SVRA) Stock Hub 2026: The November 22 PDUFA For MOLBREEVI, The IMPALA-2 Data And A Balance Sheet Built For One Decision

01 Executive Summary

Savara Inc. is a biopharmaceutical company headquartered in Yardley, Pennsylvania, listed on the Nasdaq Global Select Market, with roughly seventy employees and a single product candidate. That candidate is molgramostim inhalation solution, a recombinant human granulocyte-macrophage colony-stimulating factor delivered to the lungs through the PARI eFlow nebuliser, developed for autoimmune pulmonary alveolar proteinosis. The conditionally accepted trade name is MOLBREEVI. It is approved in no country.

Autoimmune PAP is a disease in which antibodies against GM-CSF disable the alveolar macrophages that clear surfactant from the lung. Surfactant accumulates, gas exchange deteriorates, and patients become progressively breathless. Roughly ninety per cent of all pulmonary alveolar proteinosis is the autoimmune form. Savara’s own filings put diagnosed prevalence at six to seven cases per million people in the United States, with similar or higher rates reported elsewhere. There is no approved medicine for the condition in the United States or in Europe. The standard intervention is whole lung lavage, a procedure in which a lung is washed out with saline under general anaesthesia, which the company describes in its filings as non-standardised.

The clinical case rests on IMPALA-2, a Phase 3 trial that randomised 164 patients, 81 to molgramostim and 83 to placebo, across 43 sites in 16 countries. The primary endpoint, the change from baseline at week 24 in percentage of predicted diffusing capacity of the lung for carbon monoxide adjusted for haemoglobin, was met: 9.8 percentage points against 3.8, a difference of 6.0 points with a 95% confidence interval of 2.5 to 9.4 and a p value below 0.001, published in the New England Journal of Medicine in August 2025. The separation widened at week 48 and the open-label extension data presented at the American Thoracic Society conference in May 2026 showed the treated arm at a mean 14.7-point improvement from baseline through week 96, with patients who crossed over from placebo gaining 8.8 points during weeks 48 to 96.

The regulatory path has not been straight. The rolling BLA was completed in March 2025 and refused for filing in May 2025 on manufacturing grounds, not efficacy or safety, while the company transferred drug substance manufacture from GEMA Biotech in Argentina to FUJIFILM Diosynth in the United Kingdom. The application was resubmitted in December 2025 with Fujifilm as the supplier, formally filed with Priority Review in February 2026, and extended by three months in April 2026 to a target action date of November 22, 2026. In Europe the marketing authorisation application was validated by the EMA in March 2026 with a decision expected in the first quarter of 2027, and in the United Kingdom the MHRA validated an application under a 150-day accelerated assessment in April 2026 with a decision expected in the fourth quarter of 2026.

The financial position is designed around one date. Cash, cash equivalents and short-term investments were $173.0 million at June 30, 2026, down from $235.7 million at the end of 2025, against $30.1 million of drawn debt whose first cash principal payments fall in 2028. The second quarter produced a net loss of $40.2 million, of which $7.8 million was share-based compensation, and general and administrative expense rose 78.2% year on year as the commercial organisation was assembled. On approval, and only on approval, two facilities open: up to $75 million of additional term loans from Hercules Capital and a $75 million payment from funds managed by RTW Investments in exchange for a tiered royalty on United States net sales capped at $187.5 million.

02 The November 22 Date, And How The Company Got There

The sequence matters more than the date, because the sequence is what a reviewer will have in front of them.

December 2024 to March 2025: the rolling submission

Savara began a rolling submission of the Biologics License Application in December 2024 and completed it in March 2025, requesting Priority Review. A rolling submission allows a sponsor with a Fast Track designation to file sections of an application as they are completed rather than all at once.

May 2025: refuse to file

The FDA issued a refuse-to-file letter. On the company’s account in its annual report, the letter did not rest on safety concerns and the agency did not request or recommend additional efficacy studies; the existing designations were unaffected. A Type A meeting followed, at which the company reached alignment on demonstrating comparability between drug substance made by GEMA Biotech, which supplied the material used in the trials, and drug substance made by FUJIFILM Diosynth, which was being brought in as the commercial manufacturer. A refuse-to-file decision means the agency has judged the application incomplete enough not to begin substantive review, and it cost roughly seven months.

December 2025 to February 2026: resubmission and acceptance

The application was resubmitted in December 2025 with Fujifilm as the drug substance supplier. In February 2026 the FDA formally filed it and granted Priority Review, setting a target action date of August 22, 2026. Priority Review shortens the agency’s goal from ten months to six from the filing date, and is granted where a product would provide a significant improvement in the treatment of a serious condition.

March 6, 2026: the Day 74 Letter

The Day 74 Letter is a routine communication sent about seventy-four days after submission that sets out the review timeline and flags any planned advisory committee. Savara disclosed that the letter indicated no advisory committee meeting is planned for the MOLBREEVI application. An advisory committee is a public meeting of external experts who vote on questions posed by the agency; its absence removes a scheduled public event that would otherwise have moved the stock in either direction, and generally signals that the reviewers do not see questions requiring outside adjudication. It is not a statement about the outcome.

April 15, 2026: the three-month extension

The FDA determined that Savara’s responses to information requests received during the review constituted a major amendment, which under the user-fee framework allows the agency to extend the goal date by three months to complete its assessment. The target action date moved from August 22 to November 22, 2026. In its announcement the company stated that the agency did not cite any safety, efficacy or manufacturing concerns in the correspondence. Major amendments are common where a sponsor supplies substantial new information late in a review, and the extension is the agency giving itself time to read it rather than a rejection signal, though it also means the reviewers asked for something substantial enough to require reading.

03 What The Company Actually Is

Savara has one programme. The 10-Q states it plainly: molgramostim inhalation solution is “the Company’s sole program”. There is no second asset to fall back on, no partnered pipeline throwing off milestone payments, and no revenue of any kind. The corporate history includes divested and discontinued respiratory assets, and what remains is an inhaled biologic and the organisation built to sell it.

The company outsources what it can. Drug substance is manufactured by FUJIFILM Diosynth Biotechnologies in Billingham, United Kingdom, with GEMA Biotech in Buenos Aires retained as a potential second source. Drug product is made by Patheon UK, part of Thermo Fisher Scientific. The nebuliser is the PARI eFlow, licensed exclusively for pulmonary delivery of recombinant human GM-CSF in this indication. Clinical operations for IMPALA-2 and the paediatric IMPACT study run through Parexel. Roughly seventy people manage that network, which is a very small number for a company preparing a commercial launch on two continents.

Leadership changed twice in 2026. Matt Pauls has been Chair and Chief Executive Officer since December 2020, having previously run Strongbridge Biopharma and held commercial roles at Insmed and Shire. Yasmine Wasfi became Chief Medical Officer in October 2025 and is a co-author on the IMPALA-2 publication. Robert Lutz, Chief Operating Officer since February 2023, added the finance role and became Chief Financial and Operating Officer on July 15, 2026, when David Lowrance resigned as Chief Financial and Administrative Officer for health reasons, as disclosed in the Form 8-K filed on June 8, 2026. Braden Parker has been Chief Commercial Officer since September 2024. The roles of Chair and Chief Executive are combined, with Joseph McCracken serving as Lead Independent Director.

The headquarters moved as well. The Langhorne lease terminated on June 30, 2026 and the company took roughly 10,795 square feet in Yardley, Pennsylvania under a 65-month lease effective July 1, 2026, with annual rent of about $0.3 million. The scale of that commitment is a useful calibration: a company preparing to sell a rare-disease biologic into a few hundred identified patients does not need a large building.

04 Autoimmune PAP: The Disease, The Population, The Current Treatment

Pulmonary alveolar proteinosis is a syndrome in which surfactant, the lipoprotein material that keeps the alveoli open, accumulates in the air spaces and interferes with gas exchange. In the autoimmune form, which accounts for roughly ninety per cent of cases, the cause is an antibody directed against GM-CSF. Alveolar macrophages need GM-CSF signalling to catabolise surfactant; when the signal is neutralised, clearance fails. Patients present with progressive breathlessness on exertion, cough and fatigue, typically between thirty and fifty years of age, and the disease can advance to pulmonary fibrosis, respiratory failure and, in the worst cases, lung transplantation.

Molgramostim addresses that mechanism directly by delivering GM-CSF into the lung at a dose intended to overwhelm the local autoantibody, restoring macrophage function where the disease is. Delivery matters: systemic GM-CSF circulates everywhere and reaches the alveolar space poorly, which is one reason an inhaled formulation is the approach in development rather than an injection.

How many patients

Savara’s annual report gives an estimated diagnosed prevalence of six to seven cases per million people in the United States, and notes that similar or higher prevalence has been reported elsewhere, with one study estimating Japan at three to four times that rate. Applying six to seven per million to a United States population of roughly 340 million produces something on the order of two thousand to two thousand four hundred diagnosed patients of all types, of whom about ninety per cent would be the autoimmune form. That arithmetic is a Merlintrader derivation from the company’s prevalence figure, not a company estimate, and Savara does not publish a treatable-population number in its filings. Diagnosed prevalence is also not the same as identified and treated patients, and in rare disease the gap between the two is usually large.

The company has spent money on closing that gap. In December 2023 it launched aPAP ClearPath in the United States, a no-charge third-party testing programme for GM-CSF autoantibodies run through a CLIA-certified laboratory, and in September 2024 it started a European disease-awareness campaign. Diagnostic infrastructure built before approval is what determines whether a launch finds patients in year one or year four.

What patients get today

Nothing is approved for autoimmune PAP in the United States or Europe. Whole lung lavage remains the intervention of record: under general anaesthesia one lung is ventilated while the other is repeatedly filled with saline and drained, removing accumulated material. It is performed at specialised centres, it is not standardised across institutions, and it treats the accumulation rather than the cause, so it is repeated as the disease returns. Some United States patients use pharmacy-compounded sargramostim off label; Savara states it cannot assess either the effectiveness of that practice or how many patients follow it. In Japan, sargramostim was approved for autoimmune PAP in April 2024, which establishes a regulatory precedent for the GM-CSF mechanism in this disease in one major market.

05 IMPALA-2 Read Precisely, Including The Part That Did Not Work

IMPALA-2, registered as NCT04544293, randomised 164 adults with autoimmune PAP one to one, 81 to inhaled molgramostim 300 micrograms once daily and 83 to placebo, at 43 sites in 16 countries. Entry required a diffusing capacity at or below seventy per cent of predicted and confirmed anti-GM-CSF autoantibodies. The double-blind period ran 48 weeks and was followed by a 96-week open-label period in which every patient receives active drug. Whole lung lavage was permitted as rescue. The company describes it as the largest placebo-controlled trial ever conducted in the disease, which the enrolment figures support.

The primary endpoint was met with a wide margin on a physiological measure that maps directly onto the disease mechanism. On the St George’s Respiratory Questionnaire, where lower scores mean better health status, the total score also separated significantly at week 24. Then the hierarchy broke. The New England Journal of Medicine report states that there was no significant between-group difference in the activity domain at week 24, and that consequently no statistical inference was drawn with respect to the subsequent secondary endpoints. In a pre-specified testing sequence, once a step fails, everything below it loses its confirmatory status regardless of the numbers.

That is the single most important nuance in the whole file, and it cuts both ways. Exercise capacity, the endpoint a patient would recognise as walking further without stopping, has no confirmatory claim from this trial. Savara’s own annual report describes the week 24 activity domain result as a nominally significant −7.81 points with a p value of 0.0149, and the week 48 figures as −5.99 points with p=0.1216 for the activity domain and −4.87 points with p=0.1046 for the total score. The word “nominally” is doing precise work there: it marks a number that exists outside the alpha-controlled claim. The publication and the filing agree on the substance and differ in emphasis, and reconciling the exact alpha allocation between them is not possible from the public documents.

Completion was high. 159 of 164 patients finished the 48-week double-blind period, a discontinuation rate of about three per cent, and every completer elected to enter the open-label extension. In a chronic disease with a daily inhaled treatment that is a meaningful operational result, whatever it does or does not prove about efficacy.

What happened in the first trial, and why it matters

IMPALA, the predecessor study registered as NCT02702180, enrolled 139 patients and randomised 138 to continuous molgramostim, intermittent dosing seven days on and seven off, or placebo. Its primary endpoint was the change from baseline at week 24 in the alveolar-arterial oxygen gradient, and in 2019 the company announced that the trial did not meet it. The published results in the New England Journal of Medicine in 2020 nonetheless showed the continuous arm at −12.8 mmHg against −6.6 for placebo, an estimated treatment difference of −6.2 mmHg with p=0.03, and a St George’s total score difference of −7.4 points with p=0.01. Both statements are true: the pre-specified primary analysis across the three-arm design did not deliver a claimable win, and the continuous arm separated from placebo. IMPALA-2 was redesigned on that experience, switching the primary endpoint to diffusing capacity and dropping the intermittent arm. A separate open-label study, IMPALA-X, was terminated in 2021.

06 The Open-Label Extension And What It Adds

On May 19, 2026 Savara reported data from the first 48 weeks of the ongoing open-label period of IMPALA-2, presented at the American Thoracic Society International Conference in Orlando as poster board 403 by Bruce Trapnell. Because the open-label period follows the 48-week double-blind period, those data reach week 96 counting from baseline.

The numbers, as reported by the company, are means with standard errors. Patients who received molgramostim throughout gained a further 2.8 points of predicted DLCO during weeks 48 to 96, for an overall mean increase from baseline of 14.7 points. Patients who crossed over from placebo to molgramostim at week 48 gained 8.8 points during weeks 48 to 96, which is the closest thing the programme has to a within-patient control: the same people, first on placebo, then on drug, moving when the drug starts. On the St George’s questionnaire the continuous group improved a further 3.8 points on the total score and 4.2 on the activity domain during the open-label year, for cumulative changes from baseline of −15.0 and −18.3 points, while the crossover group improved 6.5 and 7.9 points after switching.

Of the 164 patients randomised, 160 completed the double-blind period and all 160 entered the open-label period, of whom nine discontinued, a retention of about ninety-four per cent. The company reports no study discontinuations due to treatment-related adverse events. Exercise capacity was not assessed during the open-label period.

07 The Regulatory Map: Three Jurisdictions, Three Clocks

The designations accumulated over several years and each does something specific. Fast Track allows rolling submission and more frequent interaction with the review division. Breakthrough Therapy adds intensive guidance and organisational commitment from the agency. Orphan Drug designation, held in both the United States and the European Union, brings fee relief and, on approval, seven years of market exclusivity in the United States and ten in the European Union, which for a disease with no approved competitor is the commercial moat. In the United Kingdom the MHRA granted an Innovation Passport in June 2022 and Promising Innovative Medicine status in August 2022. Paediatric investigation plans were accepted by the EMA in March 2024 and the MHRA in October 2024, and a paediatric open-label study, IMPACT, registered as NCT06431776, began enrolling in October 2025.

The chief executive framed the priority explicitly in the August 11, 2026 release: “While we have regulatory applications under review across the U.S., EU, and U.K., the U.S. represents our nearest-term opportunity. Our focus is on the potential launch of MOLBREEVI in the U.S., supported by a strong balance sheet to ensure commercial readiness.” The British decision is expected first in calendar terms, in the fourth quarter of 2026, but the United States is where the money and the non-dilutive facilities are tied.

One structural feature of the application deserves attention. MOLBREEVI is a drug-device combination: a liquid biologic plus a specific nebuliser. It is regulated as a drug through the Center for Drug Evaluation and Research, with the device centre supporting the review of the nebuliser. That means the approval package contains device elements as well as biologic ones, and the 2025 refuse-to-file arose on the manufacturing side rather than the clinical one, which is a reminder of where the residual execution risk has historically sat for this programme.

08 Manufacturing, The Device, And What Each Partner Takes

A single-asset company with outsourced manufacturing has a cost structure and a set of obligations that sit outside the income statement until a product exists. The 10-K and 10-Q set them out.

Drug substance

GEMA Biotech in Argentina supplied the material used in IMPALA and IMPALA-2 under a supply agreement signed in April 2019 and amended in December 2022 and December 2023. On first marketing approval Savara owes GEMA a royalty in the low single digits of net sales in each country for up to ten years, and is subject to a purchase requirement for a percentage of the product it sells, which lapses if GEMA’s price exceeds an alternative supplier, if there is a shortage, or if GEMA fails to fill an order. FUJIFILM Diosynth was brought in under a master services agreement signed in February 2024 to take over technology transfer and commercial supply; the total estimated accumulated fees payable under that agreement and its work orders are $57.1 million. Three process performance qualification batches have been validated and the application was filed with Fujifilm as the drug substance supplier, with GEMA available as a possible second source after approval.

Drug product and device

Drug product is manufactured by Patheon UK, a division of Thermo Fisher Scientific, with a second source planned after commercialisation. The nebuliser comes from PARI Pharma of Starnberg, Germany, under a worldwide exclusive licence for pulmonary delivery of any recombinant human GM-CSF liquid formulation in this indication. Savara owes PARI approximately $0.6 million of contingent milestones tied to development activities and regulatory approval of the nebuliser, plus a royalty of 3.5% of net sales, and is barred from developing a competing inhalation device. PARI already has five FDA-approved nebulisers on the same eFlow platform, which reduces the novelty of the device component in a review.

Clinical operations

Parexel has run IMPALA-2 since January 2021 under a master services agreement; service fees, pass-through expenses and investigator fees over the life of the trial are estimated at approximately $51.3 million. The paediatric IMPACT study runs under a separate work order worth up to approximately $5.4 million depending on enrolment and site management.

Intellectual property

The European Patent Office granted patent number 4 496 611 in November 2025, covering the drug-device combination of a liquid solution and a nebuliser, jointly held by Savara and PARI, with protection running through March 2043. On July 30, 2026 the company announced that the European and Australian patent offices had granted patents on the liquid formulation itself, providing protection in those territories through March 2041. Orphan exclusivity, seven years in the United States and ten in the European Union, runs from approval and is independent of the patent estate.

09 The Financial Position

Cash, cash equivalents and short-term investments stood at $173.0 million on June 30, 2026, composed of $41.8 million of cash and equivalents and $131.2 million of short-term investments. At December 31, 2025 the same measure was $235.7 million. The half consumed $62.8 million of operating cash against $53.5 million in the first half of 2025, and financing activities were immaterial: no equity was raised in the period, and the small outflow relates to shares repurchased to cover tax on vesting restricted stock units.

The income statement shows a company that has stopped spending on trials and started spending on selling. Research and development was $22.0 million in the second quarter against $20.8 million a year earlier, an increase of 5.8% driven by personnel and share-based compensation and partly offset by lower manufacturing and regulatory consulting costs. General and administrative expense was $19.0 million against $10.7 million, an increase of 78.2%, of which $7.5 million was personnel cost as the commercial team was assembled and $0.8 million was commercial activity. The net loss was $40.2 million, or $(0.16) per share, including $7.8 million of share-based compensation. For the six months, research and development was $45.3 million, general and administrative $34.6 million, and the net loss $77.5 million.

The accumulated deficit reached $685.6 million at June 30, 2026. Total stockholders’ equity was $143.7 million and total assets $192.1 million, so the balance sheet is essentially the cash pile plus in-process research and development carried from earlier acquisitions.

Runway, stated carefully

The company’s own language in the 10-Q is that it has “sufficient capital to fund our planned activities” while noting it may need to raise more to fund development, seek approvals and begin commercialisation. There is no going-concern qualification and no explicit runway date in the filing. On the six-month burn of $62.8 million, $173.0 million represents roughly sixteen months of cash at the same rate, but the rate is not stable: a launch raises spending sharply, and an approval unlocks $150 million of facilities that would extend the position well beyond that arithmetic. The two possible November outcomes therefore produce very different balance sheets in 2027, from the same starting point.

10 Capital Structure, Dilution And The Two Facilities

The share count carries a feature that changes how the market capitalisation should be read. At June 30, 2026 there were 205,399,365 common shares issued and outstanding, and separately 48,600,212 shares underlying pre-funded warrants exercisable at $0.001 each, issued in financings between 2021 and 2025. A pre-funded warrant is economically a share: the holder has already paid all but a tenth of a cent, and exercise is a formality usually deferred for ownership-threshold reasons. The company itself treats them as outstanding when computing loss per share, which is why the weighted-average count for the second quarter was 253,569,891 against 205.4 million shares on the balance sheet.

Beyond those, 12,227,121 options, 6,973,000 restricted stock units and 4,562,000 performance stock units are reserved. The performance units vest on FDA approval of MOLBREEVI, EMA approval, a revenue target, or a combination, which ties a block of employee compensation directly to the November decision. Legacy warrants over 77,793 shares at $2.87 expire in 2027 and 2028 and are immaterial.

The debt

The Hercules Capital loan agreement of March 2025 provided an initial $30 million tranche, drawn in March 2025 and used to repay a Silicon Valley Bank facility. A first amendment on January 26, 2026 restructured the facility to a maximum of $105 million and made $75 million of additional term loans conditional on the approval milestone, split into a first tranche of up to $45 million and a second of up to $30 million, each available through the earlier of 120 days after approval or June 30, 2027. Interest runs at the Wall Street Journal prime rate with a 6.0% floor plus 1.45%, which was 8.2% at June 30, 2026. Future minimum payments begin in 2028: $11.4 million that year, $14.7 million in 2029 and $6.0 million in 2030. The lenders hold a first-priority security interest in the company’s intellectual property, which converts to a negative pledge under defined conditions. The amendment also pushed back two financial covenants, the cash requirement to April 1, 2027 and a conditional minimum revenue covenant to September 30, 2027, if market capitalisation falls below stated thresholds.

The royalty sale

On October 29, 2025 Savara agreed with funds managed by RTW Investments to receive $75.0 million on FDA approval of MOLBREEVI on or before March 31, 2027, in exchange for a true sale of the right to a tiered royalty on United States net sales. The royalty runs from 7.0% down to 1.0% by annual sales band, with the 7.0% tier rising to 9.5% for a year if the prior year’s net sales miss a specified level, and payments end when RTW has received $187.5 million. A buy-back option allows the company to terminate on a change of control within two years of receiving the money, and a $4.0 million payment may be owed to RTW on a change of control occurring before approval. Savara is generally required to use part of the proceeds to repay debt, but an intercreditor agreement lets the Hercules borrowing stay outstanding.

Read together, the structure is coherent and conditional. Approval converts a company with sixteen months of cash into one with roughly $300 million of resources and a product to sell. A complete response letter leaves the cash, the debt, the covenants and no access to either facility, and the March 31, 2027 outside date on the RTW agreement becomes a live constraint rather than a formality.

11 The Commercial Build-Out, And What The Filings Do Not Say

The clearest evidence that Savara is preparing to sell something is in the general and administrative line. It rose 78.2% year on year in the second quarter, and the company attributes the increase to share-based compensation and to headcount growth “as we build out our commercial team ahead of and in support of our planned product launch”, adding that these investments reflect a strategy to establish the commercial infrastructure necessary to support an effective and timely launch. Braden Parker has been Chief Commercial Officer since September 2024, which places the start of that build roughly two years before the current target action date.

What the filings and the August release do not contain is any operating detail about the launch: no pricing, no payer strategy, no distribution model, no sales force size, no revenue guidance, no target for patients treated in the first year. In an ultra-rare disease those choices determine almost everything about the commercial outcome, and none of them is public. Anyone modelling revenue for 2027 is building on assumptions the company has not made.

Two disclosed elements do bear on the launch. The first is aPAP ClearPath, the free autoantibody testing programme running in the United States since December 2023, which addresses the diagnosis bottleneck that limits every ultra-rare launch. The second is the paediatric IMPACT study, open since October 2025, which supports a future label extension into children and satisfies paediatric plan commitments in Europe and the United Kingdom.

The cost side of a launch is partly visible through the supply agreements: a low-single-digit royalty to GEMA on approved sales, 3.5% of net sales to PARI for the device, and, if the RTW transaction closes, 7.0% of United States net sales in the first tier, rising to 9.5% if sales miss a specified level. Those three obligations sit ahead of gross margin before a single dollar of operating cost, which is a structural feature of the model rather than a surprise.

12 Market Data And The Short Position

Three numbers in that table describe the same situation from different angles. A float of 106.86 million shares against 205.4 million shares outstanding means roughly half the common stock is held in positions the data provider does not count as freely traded. Short interest of 36.82 million shares is 34.46% of that float, one of the higher readings in the sector. And the short ratio of 20.92 says it would take about twenty-one average trading days for the short position to be covered at normal volume.

A short position of that size ahead of a binary regulatory decision is a mechanical amplifier in both directions. On an approval, covering demand meets a thin float and moves the price further than the news alone would justify. On a complete response letter, the same position becomes the profit and the covering never has to happen at any particular speed. The presence of a large short interest says nothing about which outcome is more likely; it says the price reaction will be violent either way. The mean analyst target of $10.94 is an aggregation of published price targets, most of which assume approval, and none of which is a forecast this report endorses.

13 Retail Sentiment

The recurring themes on the stream in the weeks to August 12, 2026 were the November review date, the European and Australian formulation patents announced on July 30, links to third-party commentary describing the situation as a binary bet into the PDUFA, and speculation about a takeover at prices well above the current quote. Several posters described the stream itself as quiet. None of that is evidence about the regulatory outcome, and takeover speculation on a public message board carries no information about whether any process exists. What the reading does establish is a stream with 22,690 watchers running a positive composite score into a decision, which is the configuration that produces the sharpest disappointment if the decision goes the other way.

14 The Case Made By Those Who Are Positive

What follows is the argument as its holders make it, not a Merlintrader view.

The trial worked, and it is published. IMPALA-2 met its primary endpoint with a six-point separation in diffusing capacity and a p value below 0.001, in 164 patients across 16 countries, published in the New England Journal of Medicine. For a disease with no approved therapy, that is the evidentiary bar, and it has been cleared and peer-reviewed.

The regulatory signals are constructive. Priority Review, Breakthrough Therapy, Fast Track, orphan designation on both sides of the Atlantic, and a Day 74 Letter saying no advisory committee is planned. Applications are also under review in the European Union and the United Kingdom, with the British decision expected before the American one.

The extension was procedural. The three-month delay followed the company’s own responses being classified as a major amendment, and Savara stated that no safety, efficacy or manufacturing concerns were cited in the correspondence. Priority Review survived the extension, which is not what happens when a review is in trouble.

No competition exists. Savara states in its annual report that it is not aware of any other company developing an inhaled GM-CSF for autoimmune PAP anywhere, and that there are no investigational drugs in clinical development for the disease in the United States or Europe. Approval would come with seven years of United States orphan exclusivity and ten in the European Union, on top of formulation patents to 2041 and a combination patent to 2043.

The funding is arranged, not hoped for. $173.0 million of liquidity, no cash principal payments on the debt before 2028, and $150 million of committed non-dilutive capital that opens on approval. The company has not issued equity in 2026.

The mechanism has a regulatory precedent. Sargramostim was approved for autoimmune PAP in Japan in April 2024, so a regulator has already accepted GM-CSF replacement as a treatment for this disease, albeit in a different formulation and jurisdiction.

The durability data keep pointing the same way. Ninety-eight per cent of randomised patients completed the blinded period, all completers entered the extension, retention through the open-label year was ninety-four per cent, and the crossover group improved 8.8 points of diffusing capacity after switching from placebo to drug.

15 The Case Made By Those Who Are Sceptical, And The Red Flags

One asset, one indication, one date. There is no second programme, no partner revenue and no product elsewhere. A complete response letter on November 22 removes the entire commercial case at once, and the company’s own filings describe molgramostim as its sole program.

This application has already been refused once. The May 2025 refuse-to-file cost roughly seven months and turned on manufacturing rather than clinical evidence. The commercial supplier changed between the failed submission and the accepted one, and comparability between two manufacturers of a biologic is exactly the kind of question that generates late information requests, which is what the April extension arose from.

The testing hierarchy broke. The St George’s activity domain missed at week 24, so no confirmatory inference attaches to any secondary endpoint after it. Exercise capacity, the outcome a patient would feel, carries no controlled claim from the pivotal trial. The company’s own annual report and the publication describe the same result with different emphasis.

The market is very small, and the company has not sized it. Diagnosed prevalence of six to seven per million is the only population figure in the filings. There is no company estimate of treatable patients, no pricing, no payer plan and no revenue guidance. Every revenue model in circulation is built on external assumptions.

Three royalty obligations sit ahead of gross margin. A low-single-digit royalty to GEMA, 3.5% to PARI on the device, and, on closing, 7.0% of United States net sales to RTW rising to 9.5% if sales miss a threshold, capped cumulatively at $187.5 million.

The spending has already moved as if approval were certain. General and administrative expense rose 78.2% year on year while the product remained unapproved. If the answer in November is negative, that cost base has to be reversed at speed, and $62.8 million of half-year burn against $173.0 million of liquidity does not leave a wide margin for a second review cycle without new capital.

The share count is larger than it looks. 48.6 million pre-funded warrants at $0.001 are economically shares and are already counted in loss per share. Capitalisation quoted on 205.4 million shares understates the base by roughly a quarter, which flatters every per-share comparison drawn from screening tools.

The finance function changed hands weeks before the decision. The Chief Financial and Administrative Officer resigned for health reasons effective July 15, 2026 and the Chief Operating Officer absorbed the role. The disclosed reason is health, and the timing places a combined finance and operations seat in its first months during a launch preparation and a regulatory decision.

16 Scenario Framework

The two paths below describe what would have to happen. They are not forecasts, they carry no probabilities and no price levels.

The variable that separates the two is not the clinical data, which are published, peer-reviewed and unlikely to be re-litigated. It is whether the manufacturing and comparability package assembled around the Fujifilm transfer satisfies reviewers who refused the previous version of this application. The checkpoints the company has actually disclosed are: the MHRA decision expected in the fourth quarter of 2026, the FDA target action date of November 22, 2026, the CHMP opinion and European decision expected in the first quarter of 2027, and the March 31, 2027 outside date on the RTW agreement.

17 Bottom Line

Two accurate and opposite descriptions of Savara can be held at once. The first is a company that ran the largest controlled trial ever conducted in autoimmune PAP, met its primary endpoint with a six-point diffusing-capacity separation and a p value below 0.001, published it in the New England Journal of Medicine, holds Breakthrough Therapy and orphan designations on two continents, has an application under Priority Review with no advisory committee planned, faces no competing programme anywhere, and has arranged $150 million of non-dilutive capital that opens the day it is approved. The second is a company with one asset and no revenue, whose application was refused for filing in 2025 on manufacturing grounds, whose review was extended three months in April, which has never published a treatable-population estimate or a price, which burned $62.8 million in six months while raising general and administrative spending 78.2%, and about a third of whose float is sold short into a single agency decision. Both descriptions come from the same filings.

What is verified. PDUFA target action date November 22, 2026, after a three-month extension announced April 15, 2026. Priority Review granted February 2026; Day 74 Letter of March 6, 2026 indicating no advisory committee is planned. EMA validation March 2026 with a decision expected in the first quarter of 2027; MHRA validation April 2026 under a 150-day accelerated assessment with a decision expected in the fourth quarter of 2026. IMPALA-2: 164 patients randomised 81 to 83, week 24 DLCO +9.8 against +3.8 percentage points, difference 6.0 points, 95% CI 2.5 to 9.4, p<0.001; week 48 +11.6 against +4.7; SGRQ total −11.5 against −4.9 at week 24, p=0.007; no significant difference in the activity domain, which ended the confirmatory hierarchy. Open-label extension through week 96: +14.7 points from baseline on continuous treatment, +8.8 points during weeks 48 to 96 for patients crossing over from placebo. Cash and short-term investments $173.0 million at June 30, 2026, from $235.7 million at December 31, 2025; debt $30.1 million; six-month operating burn $62.8 million; accumulated deficit $685.6 million. Second-quarter net loss $40.2 million, $(0.16) per share, with research and development at $22.0 million and general and administrative at $19.0 million. 205,399,365 common shares outstanding plus 48,600,212 shares under pre-funded warrants at $0.001. Hercules facility up to $105 million with $75 million conditional on approval; RTW payment of $75.0 million on approval by March 31, 2027 against a tiered 7.0% to 1.0% United States royalty capped at $187.5 million.

What is not verified. Whether the FDA approves, and on what label. Whether the manufacturing package now satisfies the reviewers who refused the 2025 filing. How many of the six to seven diagnosed patients per million are actually identified, referred and treated, since the company publishes no treatable-population figure. Price, payer coverage, distribution and sales force, none of which is disclosed. Any revenue expectation for 2027. The exact alpha allocation behind the differing presentations of the St George’s activity domain result in the publication and the annual report.

The dates that settle the question: the fourth quarter of 2026, for the MHRA decision in the United Kingdom; November 22, 2026, the FDA target action date on which the entire equity turns; the first quarter of 2027, for the European decision; and March 31, 2027, the outside date after which the RTW royalty payment is no longer available on approval.